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Abstract
Background: To study the relation between the prescription rates of selected cardiovascular
drugs (ACE-inhibitors and Angiotensin receptor blockers, beta-blockers, diuretics, and
combinations), sociodemographic factors (age, gender and socioeconomic class) and concomitant
diseases (hypertension, coronary heart disease, cerebrovascular accident, heart valve disease, atrial
fibrillation, diabetes mellitus and asthma/COPD) among patients with heart failure cared for in
general practice.
Methods: Data from the second Dutch National Survey in General Practice, conducted mainly in
2001. In this study the data of 96 practices with a registered patient population of 374.000 were
used.
Data included diagnosis made during one year by general practitioners, derived from the electronic
medical records, prescriptions for medication and sociodemographic characteristics collected via
a postal questionnary (response 76%)
Results: A diagnosis of HF was found with 2771 patients (7.1 in 1000). Their mean age was 77.7
years, 68% was 75 years or older, 55% of the patients were women. Overall prescription rates for
RAAS-I, beta-blockers and diuretics were 50%, 32%, 86%, respectively, whereas a combination of
these three drugs was prescribed in 18%. Variations in prescription rates were mainly related to
age and concomitant diseases.
Conclusion:  Prescription is not influenced by gender, to a small degree influenced by
socioeconomic status and to a large degree by age and concomitant diseases.
Background
General practitioners (GPs) play a central role in the diag-
nosis and management of heart failure (HF). Over half of
the patients with HF are diagnosed in primary care, and
one third is solely managed by the GPs [1,2]. In the last 15
years, new insights have changed the treatment of HF. In
the 1970s and 1980s, physicians considered heart failure
principally as a hemodynamic disorder; from the late
eighties onwards they realised that it is a neurohormonal
disorder [3] as well. The new concept has led to the recom-
mendation in most guidelines [4-6] to treat patients with
stable HF not only with diuretics, but also with inhibitors
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of the renine-angiotensin-aldosterone system (RAAS-Is)
[7,8] and beta-blockers [9-11]. Currently, angiotensin-
converting enzym-inhibitors (ACE-Is) are first choice
among the RAAS- inhibiting drugs, but in case of side
effects and adverse reactions angiotensin II receptor block-
ers (ARBs) are recommended as second choice [12,13]. In
1996, the Dutch College of General Practitioners issued
guidelines for the diagnosis and treatment of HF. These
guidelines did not include beta-blockers in the recom-
mended medication; however, in the revised version of
2004 beta-blockers were included. In addition to these
medicines digoxin [14] is still indicated in selected cases,
and for patients suffering from HF with NYHA class 3 and
4 spironolactone [15] is recommended.
Recent surveys suggest that ACE-Is and beta-blockers are
underprescribed in general practice [1-17].
The main aim of this study was to investigate the prescrip-
tion rates of RAAS-Is, beta-blockers, diuretics, spironolac-
tone and digoxin for patients diagnosed with HF in
general practice by using a nationally representative data-
base; these rates reflect the average prescription patterns in
Dutch general practice.
We have examined the prescription rates of all patients
known with HF in relation to sociodemographic (age,
gender and socioeconomic class) and morbidity charac-
teristics (specific concomitant disorders: hypertension,
coronary heart disease, cerebrovascular accident, heart
valve disease, atrial fibrillation, diabetes mellitus and
asthma/COPD). Identification of subgroups with subop-
timal treatment may guide interventions aimed at
improving the quality of pharmacological treatment by
GPs.
Methods
Design
Data were obtained from the second Dutch National Sur-
vey of General Practice (DNSGP-2), which was performed
by the Netherlands Institute for Health Services Research
(NIVEL) in 2001 [18]. In this survey, 195 GPs (165 GP full
time equivalents) in 104 practices participated with a total
practice population of 394.192 (midtime population),
comprising a 2.5% sample of the Dutch population. For
various reasons eight of the participating practices were
excluded, leaving a midtime population of 374.000 (three
practices did not deliver any morbidity data due to techni-
cal problems, the data of five practices did not meet the
required quality criteria). The participating GPs were rep-
resentative for Dutch GPs and practices with respect to
age, gender and location in deprived areas, however, sin-
gle-handed practices were underrepresented (32% instead
of 44% nation wide). The patient population is represent-
ative for the Dutch population concerning age, gender,
degree of urbanisation, social class and ethnic minority
groups, and type of health insurance. In the Netherlands,
GPs have a gatekeeper position in the health care system.
All non-institutionalised patients are registered with a GP.
Medical specialists are only accessible after referral by a
GP. If a specialist starts treatment, in nearly all cases the
GP will be responsible for the repeat prescriptions.
Measurements
Data about age, gender and type of health care insurance
(public/private) were derived from the administration of
the practices. Sociodemographic data of patients were
obtained by sending a questionnaire by mail to all listed
patients to collect data about occupational and educa-
tional status and country of birth.
Ethical approval
The study was carried out according to Dutch legislation
on privacy. The privacy regulation of the study was
approved by the Dutch Data Protection Authority.
According to Dutch legislation, obtaining informed con-
sent is not obligatory for observational studies
The overall response was 76.5%. The non-responders
showed no selection with respect to age and gender, but
the non-indigenous population was underrepresented in
the census: 12,5 percent in the response-group versus 17,5
in the Dutch population.
To examine socioeconomic gradients the data about occu-
pational and educational level were aggregated in three
socioeconomic classes: high, medium en low. The occupa-
tional level was used as primary marker for social class. In
case of unknown occupation the highest educational level
was used as indicator.
Information about morbidity was derived from the elec-
tronic medical records kept by the GP. Data included
health problems presented within a consultation during
twelve consecutive months and diagnoses were coded
using the International classification of primary care
(ICPC). Also, all GP's prescriptions were extracted and
coded according to the Anatomical Chemical Classifica-
tion system (ATC). Patients with HF were defined on the
basis of at least one contact diagnosis with ICPC code K77
during the observation year. The selected concomitant
diseases were based on their respective ICPC codes in the
same year. Hypertension, coronary heart disease, valve
diseases and atrial fibrillation are not only important
coexisting disorders but they also contribute to the devel-
opment of HF and play a key role in its progression and
response to therapy [19].
Prescription rates were calculated as proportions of
patients with HF. We used chi-square tests to compare theBMC Family Practice 2006, 7:40 http://www.biomedcentral.com/1471-2296/7/40
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effect of gender, age group, socioeconomic status and
comorbidity on prescription rates.
Results
Patient characteristics (table 1)
In total 2771 patients (7.4 in 1000) were diagnosed as suf-
fering from of heart failure: 1248 (6.7 in 1000) males and
1523 (8.1 in 1000) females. The mean age of all patients
was 77,7 years (SD 10.5) ; for males it was 75.2 (SD 10.6)
years, for women 79.7 years (SD 10.0); 1897 (68%) of all
patients were 75 years or older. From the age of 45
onwards, every decade there was a fourfold increase in the
prevalence rate of HF.
During the registration period 303 patients died; this
amounted to 11% of all known patients with HF. The
mean age of the deceased was 82.1 years.
Prescription rates (table 2)
Combination regimes
A combination of a diuretic with an RAAS-I and a beta-
blocker (triple treatment) is considered as the basic
regime for patients with HF. We investigated the various
combinations of these three drugs. This triple treatment
was used by 18% of all patients. We found statistically sig-
nificant differences between the age-groups and socio-
economic classes: the below-75 years group and the high-
est socio-economic class were prescribed more frequently
the triple treatment.
Looking at a combination of two of these three drugs, the
combination diuretics and RAAS-Is occurred in 28.2%,
diuretics and beta-blockers in 10.6%, and beta-blockers
and RAAS-Is in 1.3 percent. The combination diuretics-
RAAS-I was seen more often in the group of 75 years and
older, the combination of RAAS-I and beta-blocker more
often in the group below 75 years. Diuretics as mono-
therapy were prescribed in 29.6% of all patients, RAAS-Is
in 3.0% and beta-blockers in 1.7%. Here again significant
differences were seen between the age groups.
Prescription rates for the separate drugs
One or more diuretics were used by 86% of all patients: in
75% of the HF patients loop diuretics were involved.
RAAS-Is were prescribed in 1373 patients (50%). During
the observation year 57 patients (2%) switched from an
ACE-I to an ARB. Beta-blocking drugs were prescribed to
32% of the patients, spironolactone to 20%, and digoxin to
25%. Considering gender, no significant differences in pre-
scription rates were seen for any of the medicines under
investigation.
In the age group of 75 years and older prescription rates for
diuretics and digoxin were higher, but lower for beta-
blockers compared to the under 75 group. Socioeconomic
differences were only found for prescription of beta-
blockers with a higher rate in the highest socioeconomic
class.
Concomitant disorders
Before studying the prescription rates for concomitants
disorders, we determined in which proportion the
selected diseases occurred in our population of patients
with HF (table 3). Overall, 30% of the patients had no
comorbidity at all, 36 percent one, 23 percent two, 9 per-
cent three and 2 percent had four or more comorbidities.
Hypertension was the most common comorbidity (31%)
followed by coronary heart disease (28%), diabetes melli-
tus (20%), asthma/COPD (20%), atrial fibrillation (14%)
and CVA/TIA (8%)
Comorbidity influenced the prescription rates of the med-
icines under consideration. Patients with coronary heart
disease, hypertension and diabetes mellitus were taking in
a higher proportion nearly all drugs under study including
the triple treatment. As expected, patients with atrial fibril-
lation used more frequently digoxin and patients with
asthma or COPD less often beta-blockers. The more
comorbidities, the more medicines were used (data not
shown). RAAS-Is were used by 70% of the patients with
three or more comorbidities.
Table 1: Number of patients with HF and prevalence rate of HF by age and sex
Age Number of patients with HF Prevalence rate HF (/1000)
all male female all male female
• 0–24 5 1 4 <0.1 <0.1 <0.1
• 25–44 19 11 8 0.2 0.2 0.2
• 45–54 71 39 32 1.3 1.4 1.2
• 55–64 224 159 65 5.2 7.5 3.1
• 65–74 555 309 246 21.7 26.3 17.7
• 75 and older 1897 729 1168 91.7 96.7 85.6
• All ages 2771 1248 1523 7.4 6.7 8.1BMC Family Practice 2006, 7:40 http://www.biomedcentral.com/1471-2296/7/40
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Discussion
This study is unique as it describes the prescription pat-
terns for HF in an unselected general practice population
in the Netherlands. In comparison with HF patients in
clinical trials and in community-based studies, such a
population tend to have a higher mean age [20], a higher
proportion of women [21], and a greater percentage of HF
with preserved left ventricular function [22,23] With a
mean age of 77.7 years and a female proportion of 55%,
our study population confirmed the findings for age and
gender. About the percentage of patients with preserved
left ventricular function we have no information.
The prevalence of 7.4 in 1000 is in line with the findings
of Murphy [24] in Scotland. In most studies only the pre-
scription rates of separate drugs were explored, in this
study we investigated also the combined prescription of
diuretics, RAAS-Is and beta-blockers. This triad was pre-
scribed to approximately one out of five patients, with a
significantly higher percentage in the under 75, the higher
Table 3: Prescription rates in patients with HF in relation to comorbidity*
all CHD HT CVA/TIA AF DM Astma/COPD
N = 2771 N = 769 N = 720 N = 212 N = 387 N = 551 N = 559
Medication (%)
Triple 18 30 27 14 23 24 13
Diuretics 87 90 90 89 90 90 92
RAAS-Is 50 60 62 47 55 62 48
Beta-blockers 32 51 45 30 40 35 24
Spironolactone 20 23 21 13 21 24 22
digoxin 25 21 24 24 64 29 26
* bold figures represent statistically significant differences on the chi-square test with p < 0.05
CHD = coronary heart disease HT = hypertension AF = atrrial fibrillation DM = diabetes mellitus
Table 2: Prescription rates for diuretics, RAAS-Is, beta-blockers alone or in combination*
Medication All Sex Below or above 75 y SES
Male Female <75 y >=75 y low high
N = 2771 1248 1523 873 1898 1235 253
Triple treatment (%)
• Diuretic and 
RAAS-I and 
beta-blocker
18.0 18.4 17.7 23.7 15.4 16.7 22.1
Two Drugs (%)
• Diuretic and 
RAAS-I
28.2 29.0 27.6 21.7 31.2 30.5 26.1
• Diuretic and 
beta-blocker
10.6 9.8 11.2 11.1 10.3 10.5 10.7
• RAAS-I and 
beta-blocker
1.3 1.1 1.4 1.9 1.0 1.3 2.4
Monotherapy (%)
• Diuretic 
monotherapy
29.6 28.0 30.9 24.7 31.2 29.1 25.3
• RAAS-I 
monotherapy
3.0 3.5 2.5 4.6 2.2 2.8 3.6
• beta-blocker 
monotherapy
1.7 2.1 1.7 2.3 1.4 1.7 3.1
Prescription of every drug separately (%)
• Diuretics 86 85 88 83 88 87 83
•  R A A S - I s5 05 14 85 14 95 05 3
• Betablockers 32 32 32 40 29 31 39
• 
Spironolactone
20 20 20 20 20 21 21
• digoxin 25 23 26 19 27 25 23
* bold figures represent statistically significant differences on the chi-square test with p < 0.05BMC Family Practice 2006, 7:40 http://www.biomedcentral.com/1471-2296/7/40
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socioeconomic group and in patients with cardiovascular
comorbidity, and with no differences for gender.
Considering each group of drugs separately: RAAS-Is were
prescribed in about half of the cases with no significant
differences for gender, age and socioeconomic status. A
patient suffering from coronary heart disease, hyperten-
sion or diabetes mellitus had a chance of more than 60%
to receive a RAAS-I. This proportion increased to 70% in
case of three or more comorbidities in the same patient.
beta-blockers were prescribed to one third of all patients
with a higher proportion in the younger age-group and
highest socioeconomic class. Persons with coronary heart
disease had a prescription rate above 50 percent, patients
with hypertension and atrial fibrillation had prescription
rates above 40 percent, people suffering from asthma or
COPD had a lower rate (24%).
Our results demonstrated that age and comorbidity influ-
enced prescriptions substantially, socioeconomic class
only with regard to the triple treatment, and that gender
had no influence. In table 4 we summarize the prescrip-
tion rates in other primary care studies and compare them
with our findings. The prescription behaviour of Dutch
GPs is approximately as high as in other studies; however,
beta-blockers and spironolactone seem to be prescribed
more often in the Netherlands than in the UK. In other
studies, combination treatments of medicines were not
investigated.
Limitations of this study
As any study of this type, this study too has its limitations.
Firstly, we take the GPs' diagnosis of HF at face value, we
have no independent confirmation of the diagnosis. In
some studies, doubt has been raised about the validity of
the diagnosis heart failure made by a GP [28,29]. How-
ever, our study aimed to study the prescription behaviour
of GPs towards HF patients in primary care, so it seems
justified to take the GPs' diagnosis as point of departure.
Secondly, no data about the dosages of the medicines
involved are used. Thirdly, we have no information on the
severity of the disease in our patient group. Fourthly, we
can not differentiate between patients suffering from HF
with left ventricular dysfunction and those with preserved
left ventricular function.
How to judge our results? Is it acceptable that half of the
patients receive RAAS-Is, one in three patient a beta-
blocker and one in the five patients triple treatment?
In the IMPROVEMENT of Heart Failure Programme [1]
the primary care physician's knowledge and perceptions
about the management of HF were assessed. The conclu-
sion was that knowledge of ACE-Is was high, but the phy-
sicians were less convinced about the benefits of beta-
blockers. Guidelines for HF are largely based on surveys in
which elderly patients and patients with multiple comor-
bidities are excluded. Moreover, in most studies only
patients with HF and left ventricular dysfunction are
included, whereas patients with preserved left ventricular
function are left out. Scientific evidence about the benefi-
cial effects of RAAS-Is and beta-blockers in patients with
preserved left ventricular function is scarce [27]. In 2001,
the guidelines of the Dutch Association of General practi-
tioners did not yet recommend beta-blockers for HF.
An impression of the achievable prescription rates can be
derived from Brotons [30] and Baxter [31]. Brotons et al.
determined in a population of persons two years after
their first myocardial infarction that the achievable stand-
ard for ACE-Is was 50%, whereas 32% were actually
receiving it ; for beta-blockers these figures were 70% and
50%, respectively.
Baxter et al. determined in the setting of a geriatric outpa-
tient department the tolerability and symptoms changes
associated with the introduction of bisoprolol treatment
in older patients with HF. The bisoprolol was tolerated by
69% of the 51 patients with a mean age of 78 years. When
we apply these figures cautiously to our study population
of patients with heart failure and hypothesize that 30% of
our population had justified reasons not to use a RAAS-I,
the achievable prescription rate is 70%; with the actual
Table 4: Prescription rates in several studies
This study Pont[25] Murphy[24] Key Health Statistics[26] Rutten[27]
Country NL NL Scotland UK NL
No. of patients 2771 2493 1007 17817 103
Medication (%)
•  A C E - I 4 54 23 94 84 0
•  A R B 695 6
• Beta-blocker 32 26 21 11 9
• Spironolactone 20 11 9 11
• digoxin 25 25 22 28BMC Family Practice 2006, 7:40 http://www.biomedcentral.com/1471-2296/7/40
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prescription rate of 50% there is a gap of 20%. Only per-
sons with three or more comorbidities in our population
received RAAS-Is in a proportion of 70%.
For beta-blockers we can follow a similar reasoning.
Assuming that 80 percent of the patients is eligible for
treatment with a beta-blocker and that 30% of the
patients have justified reasons for not using it, the achiev-
able prescription rate should be 50%. Compared with the
actual rate of 32%, there is a gap of nearly 20%.
Conclusion
Considering the observed prescription rates, the conclu-
sion must be that, on the one hand, there is room for
improvement in the treatment of patients with HF in gen-
eral practice, but, on the other hand, the gap between
achievable standards and actual treatment may be smaller
than generally suggested. The influence of gender and
socioeconomic class on prescription rates is not very
marked, the influence of age and comorbidity is consider-
able.
Despite best practice, it may not be achievable for some
patients to reach the recommended medication for vari-
ous reasons, such as comorbidity, contraindications or
side effects. All these reasons will occur more often in an
elderly population. In the United States, 20 percent of the
Medicare beneficiaries have five or more chronic condi-
tions and 50 percent are receiving five or more medica-
tions [32]. Viewing disease-specific medication guidelines
from this perspective, the question raises whether what is
good for the disease is always best for the patient.
In the Netherlands, the GP has an overview of the whole
medical history of a patient. Therefore, he is in the best
position to translate disease guidelines into prescribing
decisions for individual patients with multiple chronic
conditions by weighting benefit and harm associated with
multi-drug regimes. Therefore he should be supported by
evidence and guidelines which are less disease-driven and
more patient-driven.
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